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Mean savings per patient per year compared to formoterol/budesonide, Salmeterol/
Fluticasone and Tiotropium were of COP 1,593,128.1 (USD822.9), COP 2,366,779.1 (USD 
1,222.6) and COP 8,990.6 (USD4,64). The probabilistic sensitivity analysis presented 
Glycopirronium as a dominant alternative compared to tiotroprium and formoterol/
budesonide in more than 90% of the cases and against salmeterol/fluticasone the 
results were inconclusive. ConClusions: Glycopirronium is cost-effective when 
compared to other long-acting bronchodilators in the Colombian Health Care System.
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The CoST effeCTiveneSS AnAlySiS of indACATeRol veRSuS TioTRoPium 
in A ChineSe mediCAl CoST SeTTing
Fan C.1, Dong C.H.2, Lin M.3, Chang J.3
1Zhongyu Pharmacoeconomics Research Centre, Beijing, China, 2Ministry of Human Resources and 
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objeCtives: This study evaluated the cost-effectiveness of Indacaterol (150 ug) ver-
sus Tiotropium applied to the patients with Chronic obstructive pulmonary disease 
(COPD) in Guangzhou, China. Methods: Markov model was developed to simulate 
the progress of COPD for 3 years and whole life respectively. The transfer probability in 
the Markov model and the utility of different Markov status were from the Indacaterol 
‘s clinical trial conducted in the US. Medical cost data of Chinese COPD patients 
are extracted from the Guangzhou health insure database. During the simulation, 
both the costs and utilities are annually depreciated at the rate of 3.5%. Results: 
Within 3 years, the Indacaterol group cost 20,089 CNY per capita, and gained 2.151 
QALY or 2.736 LY per capita; the Tiotropium group cost 23,616 CNY per capita and 
gained 2.143 QALY or 2.730 LY per capita. Thus, compared with the Tiotropium group, 
the Indacaterol group saved 3527 CNY and gained more 0.008 QALY or 0.006 LY for 
every patient within 3 years. In the lifetime simulation, Indacaterol group cost 66150 
CNY and gained 8.083 QALY or 10.327 LY per capita, while the Tiotropium group cost 
74915 CNY and gained 8.000 QALY or 10.230 LY per capita. Thus, compared with the 
Tiotropium group, the the Indacaterol group saved 8766 CNY and gained more 0.083 
QALY or 0.097 LY per capita in the lifetime. ConClusions: According to the medical 
costs of COPD patients in Guangzhou, China, the cost-effectiveness of Indacaterol is 
dominant over that of Tiotropium.
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eConomiC evAluATion of BudeSonide/foRmoTeRol AS mAinTenAnCe 
And RelieveR TheRAPy in PATienTS WiTh modeRATe oR SeveRe 
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bACkgRound: Asthma is a global health problem and currently it is estimated 
that 300 million people are affected. The aim of asthma treatment is to achieve 
and maintain clinical control. objeCtives: Conduct a cost-effectiveness analy-
sis of budesonide/formoterol as maintenance and reliever therapy for treatment 
of moderate or severe persistent bronchial asthma. Methods: A cost-effective-
ness analysis was performed using a decision tree that compares two treatment 
alternatives: budesonide/formoterol (maintenance and reliever) vs. salmeterol/
fluticasone (maintenance) plus salbutamol (reliever). Efficacy data was obtained 
from scientific literature and direct medical costs was obtained from institutional 
sources. A deterministic and probabilistic sensibility analysis was performed to 
determine the robustness of the model. Two measures of effectiveness were used: 
Life Years Gained without hospitalization (LYGh) and Life Years Gained without 
severe exacerbation (LYGse). Results: Budesonide/formoterol increases the time 
free from hospitalization (49.92 vs. 48.88 weeks) with an ICER (Incremental Cost-
Effectiveness Ratio) of $7,541.51and the free-time of severe exacerbations (41.08 
vs. 37.96 weeks) with an ICER of $3,322.86; both below the willingness to pay set in 
Mexico (1 GDP per capita: $10,047.00).The sensibility analysis showed consistency 
in results: budesonide/formoterol has a probability of 60% of being cost-effective in 
case of LYGh and 90% with LYGse efficacy measure vs. salmeterol/fluticasone under 
threshold ratio. ConClusions: The use of budesonide/formoterol as maintenance 
and reliever therapy is a cost-effective treatment in the Mexican Health system 
compared to salmeterol/fluticasone plus salbutamol reducing the time without a 
severe exacerbation and time in hospitalization.
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evAluATion AnAlySiS ComPARing TioTRoPium WiTh SAlmeTeRol oR 
iPRATRoPium in ChRoniC oBSTRuCTive PulmonARy diSeASe in TAiWAn
Lin C.W.
I-Shou University, Kaohsiung, Taiwan
objeCtives: This study presents a cost effectiveness of tiotropium compared to 
salmeterol or ipratropium for patients with chronic obstructive pulmonary disease 
(COPD) in Taiwan. Methods: A medical reimbursement claims databases from 
Taiwan’s National Health Insurance were used. National Health Insurance enroll-
ees who had an index event of at least one prescription claim (index medication) 
for either tiotropium, salmeterol or ipratropium during the study period (January 
1,2002-December 31,2006) and met all eligibility criteria were classified into one of 
three cohorts according to their medication use. Utilization and cost data of the 1-year 
post-index period was extracted from these 3 cohorts and used as a cost param-
eter. A published COPD probabilistic Markov model was adapted to compare the cost 
effectivenesss of tiotropium with salmeterol or ipratropium. Results: The study 
population included 3646patients (n= 1559 tiotropium cohort, n= 169 salmeterol, 
n= 1918 ipratropium).The estimated mean annual cost per patient on tiotropium was 
NT49581, on salmeterol was NT45039, and on ipratropium was NT36645.Tiotropium 
patients have better quality-adjusted life years across all comparisons. The probability 
of tiotropium being cost effective ranged from 20% to 30% at a willingness-to-pay 
of NT0 per QALY and reached at least a 70% at a willingness-to-pay of NT600000 
per QALY across comparisons. ConClusions: Tiotropium is more expensive than 
salmeterol or ipratropium in Taiwan’s National Health Insurance. Tiotropium may 
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imPACT of RoflumilAST on heAlTh CARe ReSouRCe uTilizATion And 
CoSTS in PATienTS WiTh ChRoniC oBSTRuCTive PulmonARy diSeASe in 
ReAl-WoRld SeTTingS
Corman S.1, Wan Y.2, Sun S.X.3, Gao X.1
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objeCtives: To compare real-world health care resource utilization (HCRU) and 
health care costs among patients initiated roflumilast compared to those initi-
ated other chronic obstructive pulmonary disease (COPD) medications. Methods: 
A retrospective database analysis was performed using LifelinkTM Health Plan 
Claims Database. We included patients with a diagnosis of COPD who initiated 
roflumilast (roflumilast group) or any other ≥ 3 COPD maintenance drugs (non-
roflumilast group) between May 1, 2011 and December 31, 2012. Patients must have 
been enrolled for 12 months prior to (baseline period) and 3 months after (follow-
up period) the initiation date, be ≥ 40 years old, not corticosteroid-dependent, and 
without asthma diagnosis at baseline. Office and emergency department (ED) visits, 
hospitalizations, and total health care costs were compared between study groups 
using nonparametric Wilcoxon rank-sum test. Difference-in-difference (DID) mod-
els were used to compare the change from baseline in hospitalizations and costs 
between groups while adjusting for baseline differences. Results: During the base-
line period, patients in the roflumilast group (N= 710) had significantly more office 
visits, ED visits, hospitalizations, and greater total costs than patients in the non-
roflumilast group (N= 13,501). The changes from baseline were: monthly frequency of 
office visits (0.081 in roflumilast vs 0.122 in non-roflumilast group; p= 0.01), ED visits 
(0.009 vs 0.007; p= 0.80), hospital admissions (0.002 vs 0.005; p= 0.02), and monthly 
costs ($432 vs $522; p= 0.34). After controlling for key covariates using DID models, 
roflumilast was associated with numerically lower hospital admissions (β = -0.003, 
p= 0.57) and total costs (β = -116, p= 0.62). ConClusions: Smaller increase in office 
visits, hospitalizations and total costs during follow-up from baseline was observed 
in roflumilast vs non-roflumilast group. A longer follow-up time may be needed to 
assess potential improvement in these economic outcomes.
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objeCtives: The cost of medicine is an important factor in any disease treatment. 
Strengthening health systems to provide such interventions at affordable cost to 
all children will save many lives. The present study was carried out to determine 
the total direct cost associated with the treatment of most commonly occurring ill-
ness in children. Methods: The study was carried out prospectively at a pediatric 
outpatient clinic over a period of 1 year in children (< 18 years of age). The data in 
the prescriptions of patients were captured at the time of consultation. The cost 
of treatment were calculated for three most commonly occurring diseases upper 
respiratory tract infection (URTI), acute gastroenteritis (AGE) and reactive airways 
disease (RAD). Results: A total of 2902 patients were included in the study. URTI 
(1078, of total patients) were found to be the most commonly occurring disease in 
children followed by AGE and RAD (468 and 332 patients, respectively). The aver-
age number of drug utilized for the treatment of RAD, AGE and URTI were found 
to be (3.3±0.4, 3.3±0.2 and 3.4±0.4, respectively). The average cost of treatment for 
RAD was found to be INR416±19, followed by INR184±3 and INR120±2 for AGE and 
URTI, respectively (1USD= approx INR62). Fifty seven percent of the drugs in AGE 
were prescribed from the National List of Essential Medicine (NLEM), while drugs 
prescribed from NLEM in RAD and URTI were (49% and 38%, respectively). In URTI 
maximum cost were spent on the use of Cough and Cold combinations (42%, of total 
cost spent on all drugs). While in RAD and AGE maximum cost were spent on the use 
of Steroids and Probiotics ( 33% and 43%, respectively). ConClusions: URTI were 
found to be the most commonly occurring illness in children. RAD treatment was 
found to be the most costly treatment among all. These findings help in building 
evidence regarding the cost of treatment for different childhood illness.
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CoST-effeCTiveneSS AnAlySiS of glyCoPiRRonium veRSuS TioTRoPium 
And fixed-doSe ComBinATionS (foRmoTeRol/BudeSonide And 
SAlmeTeRol/fluTiCASone) foR CoPd in The ColomBiAn heAlTh CARe 
SySTem
Giraldo L.F.1, Karpf Benavides E.2, Kraemer M.3, Thuresson P.O.4
1Universidad de La Sabana, Chía, Colombia, 2Novartis Colombia, Bogotá, China, 3Novartis 
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objeCtives: To evaluate the cost-effectiveness of Glycopirronium (once daily) com-
pared to tiotropium bromide and fixed dose combinations of Formoterol/budesonide 
and Salmeterol/fluticasone for the treatment of COPD from the Colombian Health Care 
system perspective. Methods: A Markov model was designed considering health´s 
state according to GOLD 2010 classification for COPD into mild, moderate, severe and 
very severe. The absorbing state was death. The first four stages include the possibil-
ity of presenting or not a severe exacerbation. Efficacy, based on the initial improve-
ment on FEV1, and outcomes measures were estimated by meta-analysis of published 
studies. Cycles were 3-month and the time horizon was 5 years. Discount rate for 
costs and benefits was 5% per year. Effectivity was evaluated by QALYs according to 
COPD severity. Health costs were determined from medical records from a third level 
university Hospital, from the official Colombian medication database (SISMED) and 
from estimations based on the GOLD guide recommendations for care. A probabilistic 
sensitivity analysis (PSA) was performed using the Montecarlo method. Results: An 
analysis of LYG and QALY showed that Glycopirronium was dominant compared to tio-
tropium and formoterol/budesonide and was inconclusive for salmeterol/fluticasone. 
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peanut 5 (21%), egg 3 (13%), fish 1 (4%) and fruits 1 (4%). Peanut could be reintroduced 
to all children after CRD, egg and milk after specific IgE IVD. Prior to the introduction 
of food a secondary care specialist food provocation was performed to confirm the 
IVD result. ConClusions: CRD ISAC was beneficial in 54% of the cases and in 21% 
of the cases it was critical for decision making. The aim of the study was reached as 
avoidance diets decreased by 63%. The results indicate, even with low patient recruit-
ment, it is likely that introducing ISAC IVD to traditional diagnostic algorithm can be 
considered cost-effective, with an average cost per avoided unnecessary diet for 480 
EURs per child. To confirm the findings a larger study will be executed.
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CoST effeCTiveneSS AnAlySiS of ReSPiRAToRy SynCyTiAl viRuS 
infeCTion PRoPhylAxiS in ChildRen WiTh CongeniTAl heART diSeASe
Cintra M.A.C.T, Santos M.S., Correia M.G., Tura B.R.
National Institute of Cardiology, Rio de Janeiro, Brazil
objeCtives: Respiratory syncytial virus (RSV) is the leading cause of acute lower 
respiratory illness in children under two years of age. In Brazil, the VSR is the cause 
of 54.1% of all hospitalizations for pneumonia /bronchiolitis in infants under one 
year old, reaching up to 70% during the epidemic periods. Congenital heart disease 
(CHD) is an important risk factor for morbidity and mortality of RSV infection. This 
study performed a cost effectiveness analysis of Palivizumab (PVZ) to prevent RSV 
infection in infants undergoing cardiac surgery for correction of CHD. Methods: 
Three Systematic Reviews (SR) of literature were performed, in Medline, Cochrane 
and LILACS, for efficacy, safety of PVZ and the prevalence of RSV in infants in Brazil. 
The economic evaluation developed a decision analytic model to estimate the cost-
effectiveness ratio of using PVZ for prophylaxis of RSV infection in children under-
going cardiac surgery, from the perspective of Public Health System, with the time 
horizon of the postoperatively period. Results: Efficacy search (478 titles) showed 
that PVZ reduces hospitalization for children with CHD by 45%. Safety search (67 
titles) showed that the PVZ is safe for this population and the prevalence of RSV in 
Brazil search (120 titles) showed that in children hospitalized with lower respiratory 
tract infection there is a prevalence of 24.35% of RSV infection. The analytical model 
showed an incremental cost-effectiveness ratio of USD863.3 per day of hospitalization 
avoided and incremental cost-effectiveness ratio of USD132,398.9 per complication 
avoided. ConClusions: The prevalence of RSV in Brazil is 24.35%. PVZ was effective 
and safe to prevent severe RSV infection in children under two years of age with CHD, 
but at a high cost to avoid an outcome. Its use has shown a significant decrease in 
hospitalization of children receiving medication. Studies published worldwide are 
controversial, requiring discussion for the implementation of the therapy in Brazil.
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objeCtives: Drugs for smoking cessation are considered of great importance to the 
decline of this epidemic, as smoking is the largest preventable cause of death world-
wide. This study aimed to evaluate the cost effectiveness of varenicline compared 
with bupropion and NRT (gum and patches) in the treatment of smoking population 
from São Paulo, Brazil’s city. Methods: Effectiveness data of 6-months of treatment 
were evaluated from a sample of patients (504) in the outpatient smoking care of 
Instituto do Coraçãoem São Paulo-Brasil (InCor). Direct drug costs were extracted from 
the Health System Prices Database. A Decision Tree Model was used for the analysis of 
Cost Effectiveness (CE) and Incremental Cost-Effectiveness Ratio (ICER), considering 
varenicline monotherapy as standard. Results: The CEs obtained were BRL 1.31, BRL 
1.34, BRL 1.88, BRL 3.09 and BRL 1.98 billion in the use of varenicline monotherapy, 
varenicline associated with bupropion, bupropion associated with gum, bupropion 
associated with NRT (gum and patches) and NRT in gum and patches,respectively. 
The ICERs were BRL 1.66 billion, BRL 153 million and per patient of BRL 1,400 and BRL 
138,41 for varenicline associated with bupropion and bupropion associated with gum 
respectively and ICERs for bupropion associated with NRT and isolated NRT respec-
tively were BRL 1.65 billion and BRL 164 billion (dominant). ConClusions: According 
to the results, treatment with varenicline (monotherapy) is cost effective for all com-
parators and cost saving when compared to NRT and bupropion associated with NRT.
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CoST-effeCTiveneSS AnAlySiS of A neW ePinePhRine AuTo-injeCToR foR 
The TReATmenT of food-AlleRgy ReACTionS: deCiSion modelling uSing 
SoCieTAl PeRSPeCTive
Patel A.M, Saxena K., Holdford D.A.
Virginia Commonwealth University, Richmond, VA, USA
objeCtives: Food allergy affects around 15 million Americans with an annual eco-
nomic burden of over $25 billion. Guidelines emphasize prompt use of epinephrine 
auto-injector (EAI) for emergency treatment of allergic reactions. This study was 
executed to assess the cost-effectiveness of a new EAI device among patients expe-
riencing life-threatening food-allergy reactions. Methods: An episodic Decision-
analysis model was developed to estimate the incremental cost-effectiveness ratio 
(ICER) associated with the new EAI compared to standard EAI, from a societal per-
spective. Both EAIs contain the same active drug of equal strength, but have different 
delivery systems. The model assumed a cohort of “at-risk” patients in the US popula-
tion, with moderate-to-severe food-allergy reaction. Treatment success was defined 
as epinephrine self-injection without any errors. Data were obtained from published 
sources including patient survey studies. Direct costs (drug cost, hospitalization and 
emergency department cost) and indirect costs (lost work-productivity cost) asso-
ciated with the treatments were calculated in 2013 US$. Sensitivity analyses were 
performed on drug costs and treatment success rates. TreeAge Pro 2011 software 
represent a cost-effective alternative to salmeterol and ipratropium if daily cost for 
tiotropium can be reduced to a reasonable level in Taiwan’s National Health Insurance.
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Amino ACid foRmulA AS A fiRST-line diAgnoSiS Tool in infAnTS WiTh 
CoW’S milk AlleRgy (CmA): A CoST-effeCTiveneSS AnAlySiS undeR The 
BRAziliAn PuBliC heAlTh CARe SySTem PeRSPeCTive
Castro A.P.B.M.1, Morais M.B.D.1, Cardoso A.L.1, Vieira M.C.2, Spolidoro J.V.N.3, Nishikawa A.M.4, 
Clark O.A.C.4
1Universidade de São Paulo, Brazil, 2Hospital Pequeno Príncipe, Brazil, 3Pontifícia Universidade 
Católica do Rio Grande do Sul, Brazil, 4Evidências, Campinas, Brazil
objeCtives: Cow’s milk allergy (CMA) is the main cause of food allergy in infants, 
resulting in life-threatening events such as anaphylaxis, impairment in growth 
and quality of life. CMA symptoms are also related to other diseases, making the 
differential diagnosis crucial for an earlier effective treatment, avoiding waste of 
resources. Amino acid formula (AAF) is an alternative in treatment of CMA patients, 
but it can also be used as a diagnostic tool for children with CMA suspicion, shorten-
ing the time for diagnosis, which may reduce resources use. Our goal is to estimate 
the cost-effectiveness of an alternative practice (AP) using AAF as a diagnostic tool 
for CMA followed by treatment according to current practice, compared to those 
currently (CP) used in Brazil, under the perspective of the public health care sys-
tem. Methods: A decision model was constructed depicting the CMA manage-
ment, with a time horizon until patients turned three years old, when most of CMAs 
are resolved. Model inputs were based on literature review and opinions of allergists/
gastroenterologists/pediatricians. Exchange rate was 1.00USD = 2.30BRL. Only direct 
costs were considered, such as formula, tests, allergy treatment, medical visits and 
hospital admissions. Results were shown as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed. Results: 
The CP presented rates of 25.4% and 9.3% of diseases other than CMA after 8 and 
12 weeks respectively versus 34% in 2 weeks for AP. With this difference an effec-
tive treatment could be established in a shorter time, diminishing the waste of 
resources. The final analysis showed that the AP using AAF for diagnosis is domi-
nant (USD1,345 and 900.6 non-symptomatic days) compared to CP (USD1,476 and 
876.0 non-symptomatic days). ConClusions: AP enabled an earlier CMA diagno-
sis, avoiding waste of resources, allowing the establishment of prompt effective 
treatments and leading to higher compliance with clinicians’ recommendations.
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CoST-effeCTiveneSS AnAlySiS of nuRSe-AdminiSTeRed oRAl 
CoRTiCoSTeRoidS AT TRiAge in PediATRiC ASThmA
Loncar M.1, Coyle D.1, Barrowman N.2, Zemek R.3
1University of Ottawa, Ottawa, ON, Canada, 2Children’s Hospital of Eastern Ontario Research 
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objeCtives: Despite evidence supporting the need for oral corticosteroid use in 
the management of acute pediatric asthma exacerbations, delays in administration 
are still common. This often leads to an increase in inpatient admissions and more 
time spent in the emergency department (ED). Using data from a time-series con-
trolled trial, the objective of this study was to assess the cost-effectiveness of triage 
nurse-administered oral corticosteroids (NAC) in children presenting to the ED with 
moderate to severe asthma exacerbations prior to physician assessment. Methods: 
Resource use and cost data for 644 acutely asthmatic patients enrolled in the con-
trolled trial comparing NAC with standard care was used. Analysis assessed the per 
patient health care system costs for both the NAC (after) phase and the physician-
ordered (before) phase over the trial’s 8-month follow-up. Uncertainty around esti-
mates was assessed through nonparametric bootstrapping which allowed calculation 
of the probability that NAC was cost-effective for different threshold values. Net 
benefit regression was used to estimate the incremental net benefit (INB) adjusted 
for potential confounders for reduced time in ED. Results: NAC was dominant 
over standard care as it was both less costly (Canadian $499.24 versus $724.90) and 
mean time to clinical improvement was shorter (218 minutes versus 264 minutes). 
The probability that NAC was cost-effective was greater than 0.98 for all threshold 
values of reduction in time with symptoms. Sensitivity analyses adopting various 
alternative assumptions found only modest differences in cost savings between the 
phases, but did not change the conclusions of the analysis. Results of the net benefit 
regression provided further evidence that NAC was cost-effective. ConClusions: 
Triage nurse initiation of oral corticosteroids before physician assessment is a cost-
effective strategy for treating children with moderate to severe asthma exacerbations 
in pediatric ED.
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heAlTh eConomiC BenefiT of inCluding ComPonenT ReSolved 
diAgnoSTiCS (CRd) (immunoCAP iSAC) in in viTRo diAgnoSTiC (ivd) 
AlgoRiThm in PRoSPeCTive TRiAl WiTh SuSPeCTed food AlleRgiC 
SChool ChildRen in finlAnd
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1Thermo Fisher Scientific, Uppsala, Sweden, 2University of Turku, Turku, Finland, 3Härkätie 
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objeCtives: Aim of study, in accordance to Finnish Allergy Program 2008-2018, is 
to decrease food avoidance diets by 50 %. Here focus is in algorithm with IVD and 
patient history in primary care school children. Health economic benefit of CRD, ISAC, 
is evaluated. Methods: Database analysis at Härkätie Primary Care Unit, including 
2317 school children in Finland indicated that 199 children (8.6%) are on avoidance 
diet ex. celiac disease. There is 37 (1.6 %) milk and 32 (1,4%) egg free diets. Peanut and 
hazelnut allergy is indexed for 39 children and 6 are indicated as soya allergic. History 
of anaphylaxis was noted in 7. Avoidance recommendation is provided by parents 
and has direct impact in costs and patient’s quality of life. The 199 children were 
contacted by letter, and 36 (18 %) were interviewed by physician. Of those, 24 children 
agreed to take part in the study with IVD (67%). Results: An unnecessary diet was 
concluded for 15, which is 63% of children included in the study: cow’s milk 7 (29%), 
